SBFMW Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 Jun 2024 @ 16:00):
Our systems believe the stock currently is undervalued by 0.22% compare to its pairs and should correct upwards.

Stats
Today's Volume	14 353
Average Volume	0
Market Cap	8.25M
EPS	$-2.00 ( Q1 \| 2024-05-20 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0300 (Sector) 42.63 (Industry) 30.78
ATR14	$0 (0.00%)

AERI 0.00%

ALVO 1.33%

ALVOW 6.79%

BDSI -0.09%

BFRIW -5.93%

CLVRW 0.00%

CYTHW -4.35%

ENDP 0.00%

GRVI 7.61%

HPCO 0.06%

INDV -1.59%

JUPWW -20.00%

LFCR -0.19%

LNDC -3.52%

LSDI -23.29%

PRFX -3.65%

PROCW 10.09%

QLI 6.82%

SBFMW 0.00%

SHOT 9.43%

SHPH 4.28%

Insider Trading

Date	Person	Action	Amount	type
2022-11-30	Sebaaly Camille	Buy	30 000	Common Stock
2022-10-20	Chamoun Malek	Sell	0	Common Stock, par value $0.001 per share
2022-02-18	Slilaty Steve N.	Sell	990 000	Series B Preferred Stock
2022-02-10	Natan David	Sell	0	Common Stock
2022-02-10	Keller Andrew Mark	Sell	0	Common Stock

INSIDER POWER
100.00
Last 64 transactions
Buy: 1 074 281 098 \| Sell: 315 420 609

Correlation (AI algo v.1.1b): Undervalued: 0.22% $0.0702 paired level. (The Algo Track The Changes Of The Most Correlated Stocks In Realtime And Give An Instant Update)

Sunshine Biopharma, Inc. Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Sunshine Biopharma, Inc. Financials

Annual	2023
Revenue:	$24.09M
Gross Profit:	$8.19M (33.99 %)
EPS:	$-18.52

FY	2023
Revenue:	$24.09M
Gross Profit:	$8.19M (33.99 %)
EPS:	$-18.52

FY	2022
Revenue:	$4.35M
Gross Profit:	$1.70M (39.04 %)
EPS:	$-1.760

FY	2021
Revenue:	$228 426
Gross Profit:	$110 596 (48.42 %)
EPS:	$0

Financial Reports:

No articles found.

Sunshine Biopharma, Inc. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Sunshine Biopharma, Inc.

Sunshine Biopharma, Inc., a pharmaceutical and nutritional supplement company, focuses on the research and development of anticancer drugs. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma cells; and SBFM-PL4, an anti-coronavirus treatment compound. It also offers Essential 9, a nutritional supplement tablet; and Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name, as well as develops and markets other science-based nutritional supplements. The company has a license agreement with the University of Georgia to advance the development of its anti-coronavirus lead compound, SBFM-PL4. Sunshine Biopharma, Inc. is headquartered in Pointe-Claire, Canada.